GeneNews Limited is focused on developing and commercializing molecular diagnostic tests for early detection of diseases and for personalized health management, with a primary focus on cancer-related indications. The Company offers Sentinel Principle, which is a platform technology to detect virtually any disease or medical condition from a simple blood sample. The Company also offers ColonSentry, which is a blood-based test for assessing an individual's current risk of having colorectal cancer. The Company operates within the biotechnology, molecular diagnostic and genomic biomarker industry. The Company operates in Canada and the United States, and transacts business primarily with the United States partners and suppliers. The Company's subsidiaries include GeneNews Corporation and GeneNews Inc.